Compounds that regulate quorum sensing in Staphylococcal bacteria and in particular in Staphylococcus aureus are provided. Compounds are described in formulas I, II, III, IV, V and VI herein. One or more compounds herein can be employed to inhibit QS and to thus inhibit virulence in Staphylococcus bacteria and in particular in Staphylococcus aureus. Compounds herein and pharmaceutical compositions containing one or more of these compounds are useful, for example, in treating infections of Staphylococcus bacteria and in particular of Staphylococcus aureus. Methods for treating such bacterial infections are provided.

Compounds provided are racemic, non-racemic or substantially enantiomerically pure dimers or salts or solvates thereof of formula: ##STR00001## where: W and W are S or NR.sub.1, or WCO or WCO is CHCH, where each R.sub.1 is hydrogen or an alkyl group having 1 to 3 carbon atoms; R and R are hydrogen or an straight-chain or branched alkyl group having 1-3 carbon atoms; R.sub.3 and R.sub.3 are hydrogen or a C1-C3 alkyl; X.sub.1, X.sub.1, X.sub.2 and X.sub.2 are optionally-substituted straight-chain or branched alkyl groups having 3-8 carbon atoms, optionally-substituted cycloalkyl groups having 3-12 carbon atoms; optionally-substituted aryl, optionally-substituted heteroaryl, optionally-substituted heterocycyl, optionally-substituted cycloalkylalkyl, optionally-substituted arylalkyl, optionally-substituted heteroarylalkyl and optionally-substituted heterocycylalkyl groups and L.sub.1, L.sub.1 and L.sub.2 are divalent chemical moieties. Dimers are employed to modulate quorum sensing and to thus inhibit virulence in Staphylococcus bacteria. Dimers are useful in treating infections of Staphylococcus bacteria. Methods for treating such bacterial infections are also provided.

Compounds provided are racemic, non-racemic or substantially enantiomerically pure dimers or salts or solvates thereof of formula: ##STR00001## where: W and W are S or NR.sub.1, or WCO or WCO is CHCH, where each R.sub.1 is hydrogen or an alkyl group having 1 to 3 carbon atoms; R and R are hydrogen or an straight-chain or branched alkyl group having 1-3 carbon atoms; R.sub.3 and R.sub.3 are hydrogen or a C1-C3 alkyl; X.sub.1, X.sub.1, X.sub.2 and X.sub.2 are optionally-substituted straight-chain or branched alkyl groups having 3-8 carbon atoms, optionally-substituted cycloalkyl groups having 3-12 carbon atoms; optionally-substituted aryl, optionally-substituted heteroaryl, optionally-substituted heterocycyl, optionally-substituted cycloalkylalkyl, optionally-substituted arylalkyl, optionally-substituted heteroarylalkyl and optionally-substituted heterocycylalkyl groups and L.sub.1, L.sub.1 and L.sub.2 are divalent chemical moieties. Dimers are employed to modulate quorum sensing and to thus inhibit virulence in Staphylococcus bacteria. Dimers are useful in treating infections of Staphylococcus bacteria. Methods for treating such bacterial infections are also provided.

The present invention relates to the field of polymerisation catalysts, and systems comprising said catalysts for polymerising carbon dioxide and an epoxide, a lactide and/or lactone, and/or an epoxide and an anhydride. The catalyst is of formula (I):

##STR00001##

Wherein M.sub.1 and M.sub.2 are independently selected from Zn(II), Cr(II), Co(II), Cu(II), Mn(II), Ni(II), Mg(II), Fe(II), Ti(II), V(II), Cr(III)-X, Co(III)-X, Ni(III)-X, Mn(III)-X, Fe(III)-X, Ca(II), Ge(II), Al(III)-X, Ti(III)-X, V(III)-X, Ge(IV)-(X).sub.2 or Ti(IV)-(X).sub.2. R.sub.3A is different from R.sub.3B; and/or at least one occurrence of E.sub.3, E.sub.4, E.sub.5 and E.sub.6 is different to a remaining occurrence of E.sub.3, E.sub.4, E.sub.5 and E.sub.6. A ligand, a process of asymmetric N-substitution of a symmetrical ligand and a process for the reaction of: (i) carbon dioxide with an epoxide; (ii) an epoxide and an anhydride; and/or (iii) a lactide and/or a lactone, in the presence of a catalyst is also described.

The present invention relates to the field of polymerisation catalysts, and systems comprising said catalysts for polymerising carbon dioxide and an epoxide, a lactide and/or lactone, and/or an epoxide and an anhydride. The catalyst is of formula (I):

##STR00001##

Wherein M.sub.1 and M.sub.2 are independently selected from Zn(II), Cr(II), Co(II), Cu(II), Mn(II), Ni(II), Mg(II), Fe(II), Ti(II), V(II), Cr(III)-X, Co(III)-X, Ni(III)-X, Mn(III)-X, Fe(III)-X, Ca(II), Ge(II), Al(III)-X, Ti(III)-X, V(III)-X, Ge(IV)-(X).sub.2 or Ti(IV)-(X).sub.2. R.sub.3A is different from R.sub.3B; and/or at least one occurrence of E.sub.3, E.sub.4, E.sub.5 and E.sub.6 is different to a remaining occurrence of E.sub.3, E.sub.4, E.sub.5 and E.sub.6. A ligand, a process of asymmetric N-substitution of a symmetrical ligand and a process for the reaction of: (i) carbon dioxide with an epoxide; (ii) an epoxide and an anhydride; and/or (iii) a lactide and/or a lactone, in the presence of a catalyst is also described.

A polyester film including a cyclic carbodiimide compound represented by the following Formula (O-1) has good film thickness uniformity without increase in viscosity. R.sup.1 and R.sup.5 represent an alkyl group, an aryl group, or an alkoxy group; R.sup.2 to R.sup.4 and R.sup.6 to R.sup.8 represent a hydrogen atom, an alkyl group, an aryl group, or an alkoxy group; X.sup.1 and X.sup.2 represent a single bond, O, CO, S, SO.sub.2, NH, or CH.sub.2; and L.sup.1 represents a divalent linking group. ##STR00001##

A polyester film including a cyclic carbodiimide compound represented by the following Formula (O-1) has good film thickness uniformity without increase in viscosity. R.sup.1 and R.sup.5 represent an alkyl group, an aryl group, or an alkoxy group; R.sup.2 to R.sup.4 and R.sup.6 to R.sup.8 represent a hydrogen atom, an alkyl group, an aryl group, or an alkoxy group; X.sup.1 and X.sup.2 represent a single bond, O, CO, S, SO.sub.2, NH, or CH.sub.2; and L.sup.1 represents a divalent linking group. ##STR00001##

The present invention relates to the field of polymerisation catalysts, and systems comprising these catalysts for polymerising carbon dioxide and an epoxide, a lactide and/or lactone, and/or an epoxide and an anhydride. The catalyst is of formula (I):

##STR00001##

wherein at least one of M.sub.1 or M.sub.2 is selected from Ni(II) and Ni(III)-X. A process for the reaction of carbon dioxide with an epoxide; an epoxide and an anhydride; and/or a lactide and/or a lactone in the presence of the catalyst is also described.

Disclosed herein are, inter alia, activators of K2P potassium channels and pharmaceutical compositions thereof, and methods comprising their use for the treatment of diseases or adverse conditions related to low TREK family protein activity.

Disclosed herein are, inter alia, activators of K2P potassium channels and pharmaceutical compositions thereof, and methods comprising their use for the treatment of diseases or adverse conditions related to low TREK family protein activity.